表紙
市場調査レポート

細菌性市中肺炎:パイプライン製品の分析

Community-Acquired Bacterial Pneumonia - Pipeline Review, H2 2014

発行 Global Markets Direct 商品コード 257797
出版日 ページ情報 英文 67 Pages
即納可能
価格
本日の銀行送金レート: 1USD=105.42円で換算しております。
Back to Top
細菌性市中肺炎:パイプライン製品の分析 Community-Acquired Bacterial Pneumonia - Pipeline Review, H2 2014
出版日: 2014年11月18日 ページ情報: 英文 67 Pages
概要

当レポートでは、細菌性市中肺炎に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新の動向、最新の概要、最新ニュースなどを提供して、概略以下の構成でお届けいたします。

目次

イントロダクション

細菌性市中肺炎の概要

治療薬の開発

  • パイプライン製品:概要
  • パイプライン製品:比較分析

開発中の治療薬:企業別

パイプライン製品の概要

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品

開発中の製品:企業別

治療薬の開発に従事している企業

  • Melinta Therapeutics, Inc
  • Cubist Pharmaceuticals, Inc.
  • Nabriva Therapeutics AG
  • Tetraphase Pharmaceuticals Inc.
  • Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd.
  • Furiex Pharmaceuticals, Inc.
  • Biota Pharmaceuticals, Inc.

治療薬の評価

  • 単独療法の場合
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子の種類別

薬剤のプロファイル

  • solithromycin
  • faropenem
  • BC-3781
  • radezolid
  • avarofloxacin hydrochloride
  • solithromycin
  • TP-834
  • TP-271
  • GyrB/ParE 抗生物質
  • RNA 50Sを抑制する小分子

パイプライン製品の最新動向

開発が休止状態の製品

開発が中止された製品

製品開発のマイルストーン

  • 最新ニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC5736IDB

Summary

Global Markets Direct's, 'Community-Acquired Bacterial Pneumonia - Pipeline Review, H2 2014', provides an overview of the Community-Acquired Bacterial Pneumonia's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Community-Acquired Bacterial Pneumonia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Community-Acquired Bacterial Pneumonia and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Community-Acquired Bacterial Pneumonia
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Community-Acquired Bacterial Pneumonia and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Community-Acquired Bacterial Pneumonia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Community-Acquired Bacterial Pneumonia pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Community-Acquired Bacterial Pneumonia
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Community-Acquired Bacterial Pneumonia pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Community-Acquired Bacterial Pneumonia Overview
  • Therapeutics Development
    • Pipeline Products for Community-Acquired Bacterial Pneumonia - Overview
    • Pipeline Products for Community-Acquired Bacterial Pneumonia - Comparative Analysis
  • Community-Acquired Bacterial Pneumonia - Therapeutics under Development by Companies
  • Community-Acquired Bacterial Pneumonia - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Community-Acquired Bacterial Pneumonia - Products under Development by Companies
  • Community-Acquired Bacterial Pneumonia - Companies Involved in Therapeutics Development
    • Cubist Pharmaceuticals, Inc.
    • Furiex Pharmaceuticals, Inc.
    • Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd.
    • Melinta Therapeutics, Inc
    • Nabriva Therapeutics AG
    • Tetraphase Pharmaceuticals Inc.
  • Community-Acquired Bacterial Pneumonia - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • acorafloxacin - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BC-3781 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DBAF-301 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • faropenem medoxomil - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • radezolid - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit 23S Ribosomal RNA for Infections - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • solithromycin - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TP-271 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TP-834 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Community-Acquired Bacterial Pneumonia - Recent Pipeline Updates
  • Community-Acquired Bacterial Pneumonia - Dormant Projects
  • Community-Acquired Bacterial Pneumonia - Discontinued Products
  • Community-Acquired Bacterial Pneumonia - Product Development Milestones
    • Featured News & Press Releases
      • Sep 25, 2014: Cempra Completes Enrollment of Solitaire-Oral Phase 3 Trial
      • Feb 20, 2014: Cempra Initiates Solithromycin Pediatric Program
      • Dec 16, 2013: Cempra Provides Update on Clinical Development of Solithromycin
      • Sep 10, 2013: Cempra to Present Data at ICAAC on Solithromycin's Activity Against a Broad Range of Pathogens Including Four Proposed or Designated by the Food and Drug Administration as Qualified Infectious Disease Pathogens Under the Generating Antibiotic Incentives Now Act
      • Sep 06, 2013: Cempra's Solithromycin Receives Qualified Infectious Disease Product Designation From the U.S. Food and Drug Administration
      • Jun 13, 2013: Cempra Provides Guidance On Phase III Clinical Program Required For Regulatory Approval Of Solithromycin For Community-Acquired Bacterial Pneumonia
      • May 28, 2013: Cempra Receives $58m Contract To Develop Antibiotic For Pediatric Use And Biodefense From BARDA
      • May 20, 2013: Cempra Presents Post-Phase II Analysis Of Solithromycin's Efficacy And Safety Results From Patients With Community Acquired Bacterial Pneumonia
      • Apr 29, 2013: Tetraphase Pharma Announces Presentation Of Data On Preclinical Candidate TP-271 At ECCMID 2013
      • Dec 19, 2012: Cempra Announces Initiation Of Oral Solithromycin Global Phase III Clinical Trial In Patients With Community-acquired Bacterial Pneumonia
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Community-Acquired Bacterial Pneumonia, H2 2014
  • Number of Products under Development for Community-Acquired Bacterial Pneumonia - Comparative Analysis, H2 2014
  • Number of Products under Development by Companies, H2 2014
  • Comparative Analysis by Late Stage Development, H2 2014
  • Comparative Analysis by Clinical Stage Development, H2 2014
  • Comparative Analysis by Early Stage Development, H2 2014
  • Products under Development by Companies, H2 2014
  • Community-Acquired Bacterial Pneumonia - Pipeline by Cubist Pharmaceuticals, Inc., H2 2014
  • Community-Acquired Bacterial Pneumonia - Pipeline by Furiex Pharmaceuticals, Inc., H2 2014
  • Community-Acquired Bacterial Pneumonia - Pipeline by Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd., H2 2014
  • Community-Acquired Bacterial Pneumonia - Pipeline by Melinta Therapeutics, Inc, H2 2014
  • Community-Acquired Bacterial Pneumonia - Pipeline by Nabriva Therapeutics AG, H2 2014
  • Community-Acquired Bacterial Pneumonia - Pipeline by Tetraphase Pharmaceuticals Inc., H2 2014
  • Assessment by Monotherapy Products, H2 2014
  • Number of Products by Stage and Target, H2 2014
  • Number of Products by Stage and Mechanism of Action, H2 2014
  • Number of Products by Stage and Route of Administration, H2 2014
  • Number of Products by Stage and Molecule Type, H2 2014
  • Community-Acquired Bacterial Pneumonia Therapeutics - Recent Pipeline Updates, H2 2014
  • Community-Acquired Bacterial Pneumonia - Dormant Projects, H2 2014
  • Community-Acquired Bacterial Pneumonia - Discontinued Products, H2 2014

List of Figures

  • Number of Products under Development for Community-Acquired Bacterial Pneumonia, H2 2014
  • Number of Products under Development for Community-Acquired Bacterial Pneumonia - Comparative Analysis, H2 2014
  • Number of Products under Development by Companies, H2 2014
  • Comparative Analysis by Early Stage Products, H2 2014
  • Assessment by Monotherapy Products, H2 2014
  • Number of Products by Top 10 Targets, H2 2014
  • Number of Products by Stage and Top 10 Targets, H2 2014
  • Number of Products by Top 10 Mechanism of Actions, H2 2014
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014
  • Number of Products by Top 10 Routes of Administration, H2 2014
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2014
  • Number of Products by Top 10 Molecule Types, H2 2014
  • Number of Products by Stage and Top 10 Molecule Types, H2 2014
Back to Top